image credit- shutterstock
Laborate Pharmaceuticals, one of India’s leading pharmaceutical manufacturing and export companies, is currently in advanced discussions with partners in the EU and UK for the co-development and commercial supply of finished formulations, with projected international revenue growth of over $100 million over the next five years.
The company recently announced that its manufacturing site in Laborate Pharmaceuticals India Ltd, 111, Paonta Sahib, ( HP) has been granted the EU-GMP (European Union - Good Manufacturing Practice) certification from the relevant European regulatory agency.
The facility certification provides a path to filing regulatory dossiers for multiple products in the EU market. The company intends to file 20 dossiers over the next 5 months to obtain approvals in Europe, UK, Australia and South Africa. The company is also exploring additional certifications via authorities such as GCC, EAEU to enhance its presence in regulated markets.
"We are focused on establishing longer-term partnerships with global companies that value reliable and scalable manufacturing at a cost-effective and compliant basis," said Parag Bhatia, Director, Laborate Pharmaceuticals.
